Clinical Trials Logo

Clinical Trial Summary

Osteoporotic vertebral fracture (VF) and osteonecrosis of the femoral head (OFH) are major concerns in patients with systemic rheumatic diseases treated with high-dose glucocorticoids (GCs). The investigators examined and compared the incidence and risk factors of VF with those of OFH in patients who had recently received high-dose GC therapy to clarify the relationship between these two complications.


Clinical Trial Description

Patients with rheumatic diseases receiving GCs (≧0.5 mg/kg/day for prednisolone equivalent) within the past 2 months were enrolled in this study, and treated with 200 mg/day of etidronate cyclically. The bone mineral density (BMD) of lumbar spines (L2-4) was examined by QDR2000. OFH was evaluated by magnetic resonance imaging (MRI). ClinicalTrials.gov identifier: NCT00679978.

Forty-four patients completed the 2-year study including annual X-rays and the BMD analysis. MRI evaluation at entry and 2 years was performed in 41 patients. The BMD values with anteroposterior (AP) and lateral views decreased by 6.4% and 9.7% respectively in the first year, but were stable in the second year. Eleven patients developed VF and 9 patients developed OFH. The risk factors for VF included previous VF and a low BMD value (T score < -1.5) of AP view at baseline with odds ratio (OR) 14.9 (95%CI 2.9-76.4), while the risk factor for OFH was the recent maximum GC dosage (>1.2 mg/kg/day versus ≦; OR=7.7, 95%CI 1.3-45.5) and the decrease in BMD value of lateral view (>15% versus ≤; OR=6.7, 95% CI 1.2-36.1) in the first year. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00679978
Study type Observational
Source Saitama Medical University
Contact
Status Completed
Phase Phase 4
Start date January 2001
Completion date October 2007

See also
  Status Clinical Trial Phase
Withdrawn NCT04976972 - A Comparison of Patients Receiving a Total Knee Replacement With Robotic Assistance or With Conventional Instrumentation N/A
Completed NCT04042792 - Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate
Recruiting NCT05554029 - Coronaphobia in Rheumatic Diseases N/A
Completed NCT02944448 - A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee Phase 2
Completed NCT02694796 - Impact of Web and Smartphone-based Physical Activity Program on Physical Activity Level 12 Months After a Balneotherapy N/A
Completed NCT02256098 - RSA RCT: ATTUNE™ TKA Versus PFC Sigma TKA N/A
Completed NCT02269254 - Persona Versus NexGen N/A
Completed NCT00642837 - A Study on Health - Related Quality of Life in Patients With Rheumatic Diseases Taking Tramadol 37.5mg/Acetaminophen 325mg Tablets Phase 4
Active, not recruiting NCT04704544 - Effectiveness of Tele-rheumatology for Delivering High Quality Rheumatology Care During the COVID-19 Crisis (EVOLVE) N/A
Completed NCT05026853 - Patient-Reported Outcomes Measurement Information System Integration Into Rheumatology Clinical Practice N/A
Active, not recruiting NCT04631965 - Healthcare Transition of Adolescents With Chronic Health Conditions
Recruiting NCT00024479 - Natural History of Rheumatic Diseases in Minority Communities
Completed NCT05031104 - Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis N/A
Not yet recruiting NCT04567576 - Predictive Factors for COVID-19 in Rheumatology
Completed NCT02291471 - Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers Phase 1
Completed NCT01227694 - Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis Phase 1/Phase 2
Recruiting NCT01071447 - Nurse-led Clinic for Patients With Rheumatic Diseases and Biological Treatment N/A
Active, not recruiting NCT05618782 - Clinical Trial to Evaluate the Efficacy and Safety of LEVI-04 in Patients With Osteoarthritis of the Knee Phase 2
Active, not recruiting NCT05543642 - The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) Phase 4
Active, not recruiting NCT02694185 - Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications N/A